Sphere

Sphere

Primary Investigator: Engel

Drug/Device Information
To further outline the clinical characteristics, outcomes and dosing/titration regimens of patients treated with Uptravi in routine clinical practice
Uptravi (selexipag) is an orally available non-prostanoid IP receptor agonist recently approved by the US Food and Drug Administration (FDA)
Observational drug registry
Actelion Pharmaceuticals US, Inc.